Stock listing
A41MFQ Stock Price, News, Filings & Events — Promis Neurosciences Inc.
Selected listing: A41MFQ · LS · EUR · DE
This page tracks Promis Neurosciences Inc.'s A41MFQ:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A41MFQ:LS. A41MFQ:LS is the stock-level entry point for investors researching Promis Neurosciences Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A41MFQ:LS
- Asset type
- Stock
- Market cap
- $123.6M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- LS
- Currency
- EUR
Promis Neurosciences Inc. A41MFQ:LS stock context
This page tracks Promis Neurosciences Inc.'s A41MFQ:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A41MFQ:LS. A41MFQ:LS is the stock-level entry point for investors researching Promis Neurosciences Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Promis Neurosciences Inc.
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
September 1, 2026
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
August 13, 2026
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
August 3, 2026
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer...
July 28, 2026
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheim...
July 27, 2026
Research Promis Neurosciences Inc.
Promis Neurosciences Inc. investor report
Review AI stock analysis and investor report context for A41MFQ:LS.
Promis Neurosciences Inc. company profile
View the public company page for Promis Neurosciences Inc. on 6ix.
Promis Neurosciences Inc. news
Read company news and market updates connected to Promis Neurosciences Inc..
Promis Neurosciences Inc. investor events
Find investor webinars, events, and replay context for Promis Neurosciences Inc..
Alternate listings
PMN:NASDAQ
US · USD
Alternate listing for Promis Neurosciences Inc.; the primary context on this page is A41MFQ:LS.
A41MFQ:LSX
DE · EUR
Alternate listing for Promis Neurosciences Inc.; the primary context on this page is A41MFQ:LS.
PMN:BOATS
US · USD
Alternate listing for Promis Neurosciences Inc.; the primary context on this page is A41MFQ:LS.
23J:DUS
DE · EUR
Alternate listing for Promis Neurosciences Inc.; the primary context on this page is A41MFQ:LS.
23J:FWB
DE · EUR
Alternate listing for Promis Neurosciences Inc.; the primary context on this page is A41MFQ:LS.
23J:SWB
DE · EUR
Alternate listing for Promis Neurosciences Inc.; the primary context on this page is A41MFQ:LS.